CDC correlates with CD20 expression levels in all patients (CLL, PLL, and MCL).

The CD20 MFIs of the 33 B-CLL, 5 PLL, and 6 MCL patients were plotted against the relative lysis obtained with rituximab and complement for the same patients. The results of the statistical analysis are shown.